Factor market – Resource KT http://resourcekt.co.uk/ Fri, 11 Jun 2021 19:16:14 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.2 https://resourcekt.co.uk/wp-content/uploads/2021/03/cropped-icon-32x32.png Factor market – Resource KT http://resourcekt.co.uk/ 32 32 Product Responsibility Series: Does Arkansas Recognize Market Share Responsibility As A Theory of Responsibility? | Mitchell, Williams, Selig, Gates & Woodyard, PLLC https://resourcekt.co.uk/product-responsibility-series-does-arkansas-recognize-market-share-responsibility-as-a-theory-of-responsibility-mitchell-williams-selig-gates-woodyard-pllc/ Fri, 11 Jun 2021 17:34:24 +0000 https://resourcekt.co.uk/product-responsibility-series-does-arkansas-recognize-market-share-responsibility-as-a-theory-of-responsibility-mitchell-williams-selig-gates-woodyard-pllc/

Download PDF

No. Arkansas did not adopt alternative liability or market share, but retained the traditional requirement of immediate cause in all tort cases. See Woodward v. Blythe, 249 Ark. 793, 462 SW2d 205 (1971). To prove a product liability case in Arkansas, a plaintiff must prove that a product manufactured or distributed by the named defendant caused him injury. See Chavers v. Gen. Motors Corp., 349 Ark. 550, 79 SW3d 361, 369–70 (2002); Jackson v. Anchor Packing Co., 994 F.2d 1295, 1303 (8th Cir. 1993) (observing that “Arkansas plaintiffs must present sufficient evidence to allow a jury to conclude that their exposure to the product is more likely than not. of a particular defendant was an important factor in producing their injuries “); Fields c. Wyeth, Inc., 613 F.Supp.2d 1056, 1060 (WD Ark. 2009) (“A basic requirement of product liability claims under Arkansas law is product identification, that is, that is, the actual product manufactured or distributed by the defendant caused harm to the plaintiff. ”).

All of this stems from the Arkansas Product Liability Act, which broadly defines “product liability claim” to include “all actions brought for or as a result of bodily injury, death or property damage caused by or resulting from the manufacturing, construction, design,. .. warning, instruction, marketing, packaging or labeling of any product ”, and this broad language encompasses the various claims of a claimant, regardless of their recovery theory. Ark. Code Ann. § 16-116-102 (5). But a claimant must still meet the Arkansas product identification requirement necessary to make a product liability claim. See Bell v. Pfizer, Inc., 716 F.3d 1087, 1092 (8th Cir. 2013). When a claimant cannot meet this requirement, such as an inappropriate attempt to rely on market share liability, a claim fails at the motion to dismiss stage.

This article is part of the Mitchell Williams Product Liability Series and explains the nuances of how Arkansas Product Liability Law is interpreted and applied.

Corneal ulcer pipeline analysis shows new https://resourcekt.co.uk/corneal-ulcer-pipeline-analysis-shows-new/ Fri, 11 Jun 2021 01:00:00 +0000 https://resourcekt.co.uk/corneal-ulcer-pipeline-analysis-shows-new/

Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) – Corneal Ulcer Pipeline Analysis Demonstrates New Therapies on the Horizon That Should Transform the Treatment Paradigm | SearchInsight

The majority of corneal ulcer drugs are in the early stages of development and in the coming years the market is expected to grow.

DelveInsight’s Corneal ulcer pipeline overview The report provides the current therapeutic landscape and a rich analysis of ongoing therapies at different stages of development, from preclinical to late stage, as well as dormant, inactive and abandoned therapeutic agents.

Some of the key points of the Corneal ulcer pipeline report:

  • The Corneal Ulcer Pipeline report offers a rich analysis of 6+ key pharmaceutical companies and 6+ key therapies.
  • The corneal ulcer pipeline includes therapies at different stages of testing such as SREC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, among others.
  • Leading pharmaceutical companies working on corneal ulcer pipeline robustness include Recordati / Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, among others.
  • FDA granted Orphan drug designation to the experimental product Recordati Rare Diseases REC 0559 for the treatment of neurotrophic keratitis.

Find out more about the pharmaceutical company and the therapy expected to gain maximum share by requesting a sample report @ Emerging therapies and predictions for corneal ulcer

Corneal ulcer: overview

Corneal ulcer, also known as keratitis, is characterized by damage or loss of the epithelial layer associated with infiltration of the underlying corneal stroma.

Although the treatment of refractory corneal ulcers is difficult, it is essential that they be resolved as they can quickly endanger the anatomical integrity of the ocular surface or the transparency of the cornea.

To learn more about the disease outlook, available therapies, and emerging medications, visit Corneal ulcer pipeline analysis

Corneal ulcer drug pipeline assessment

Drug Company Phase MoA RdA
REC 0559 Recording technique / Mime Phase II Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists Eye drops solution
OC01 Oyster Point Pharmacy Preclinical Alpha4 beta2 nicotinic receptor agonists N / A
CSB-001 Claris Biotherapeutics Phase I / II N / A Ophthalmic solution
BD-111 Shanghai BDgene Phase I / II Mechanism not defined corneal injection
NRO-1 Neuroptika Phase I Neurotrophic factor agonists derived from the glial cell line Topical
Rose bengal sodium Provectus Biopharmaceuticals Preclinical Cell death stimulants; Cell membrane modulators; Stimulants of dendritic cells; Immunostimulants; interferon modulators; interleukin 17 modulators; Interleukin-22 modulators Topical

Sample request to find out more @ Corneal Ulcer Pipeline Analysis, Key Companies and Futuristic Trends

Therapeutic evaluation of corneal ulcer

The Corneal Ulcer Pipeline report presents comprehensive coverage of active pipeline candidates segmented by stage, product type, route of administration (RoA), molecule type, target and mechanism of action (MoA).

By product type

By step

  • Discovery
  • Pre-clinic
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By molecule type

  • Monoclonal antibody
  • Peptides
  • Polymer
  • Small molecule
  • Genetical therapy
  • type of product

By route of administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule type

By mechanism of action

  • Nerve growth factor receptor agonists
  • Neurotrophic factor agonists derived from the glial cell line
  • Alpha4 beta2 nicotinic receptor agonists
  • Autophagy inhibitors
  • Cell membrane modulators
  • Autophagy inhibitors

By targets

  • Nerve growth factor receptor
  • Neurotrophic factor derived from the glial cell line
  • Nicotinic receptor alpha4 beta2

Connect with our Business Executive to Asset prioritization services and advisory solutions

Scope of the Corneal Ulcer Pipeline Report

Blanket: Global
Key players: Recordati / Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, OcuNexus Therapeutics, Santen SAS, FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Medicine Therapeutics, AmebaGone, Inc. other.
Key pipeline therapies for corneal ulcer: REC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium and others.

Go to @ Corneal ulcer pipeline: new therapies and emerging technologies


1 Presentation of the report
2 Overview of corneal ulcer
3 Corneal ulcer pipeline therapy
4 Therapeutic evaluation
5 Corneal Ulcer – Analytical Perspective from DelveInsight
6 In-depth business assessment
7 Corneal ulcer collaboration offers
8 Therapeutics for corneal ulcer in clinical stage
9 Non-clinical corneal ulcer therapeutics
ten Analysis of the therapeutic pipeline against corneal ulcer
11 Inactive Corneal Ulcer Pipeline Products
12 Key Corneal Ulcer Companies
13 Key products for corneal ulcer
14 Corneal Ulcer – Unmet Needs
15 Corneal Ulcer Market Drivers and Barriers
16 Corneal Ulcer – Future Perspectives and Conclusion
17 Corneal ulcer analyst opinions
18 appendix
19 Methodology of the report
20 Consulting services
21 Warning
22 About DelveInsight

Learn more about the reporting offerings @ Ongoing therapies, treatments and clinical trials for corneal ulcer

Associated reports
Corneal ulcer market
DelveInsight’s “Corneal Ulcer – Market Overview, Epidemiology, and Market Forecast-2030” report.
Peptic Ulcer Bleeding Market
DelveInsight’s “Peptic Ulcerative Hemorrhage – Market Overview, Epidemiology and Market Forecast-2030” report.
Varicose Ulcer Market
DelveInsight’s “Varicose Ulcer – Market Overview, Epidemiology, and Market Forecast-2030” report.
Venous Leg Ulcer Market
DelveInsight’s “Venous Leg Ulcer – Market Overview, Epidemiology, and Market Forecast-2030” report.

Similar Items
Global burden of cytomegalovirus seroprevalence
Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte and others.

About SearchInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance. Get hassle-free access to all healthcare and pharmaceutical market research reports through our subscription platform PharmaDelve.

For more information visit Pharmaceutical, medical and biotechnology news

		The explosion of data drives the American social determinants of
		Thu, 10 Jun 2021 07:48:33 +0000


New York, June 10, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Explosion of Data Drives the US Social Determinants of Health Market” – https://www.reportlinker.com/p06090608/?utm_source = GNW

In fact, many non-medical SODH are important factors in a patient’s care path. As the world emerges from the global COVID-19 pandemic, there has been renewed interest in using SDOH as a component of a patient’s medical history.

SDOH can play an important role in improving the health of millions of people. Patients can benefit from knowing how lifestyle factors affect their quality of life for many years to come. Despite long-term awareness of SDOH, the concept is in an early stage of large-scale deployment. Analyst estimates that by the end of 2020, 40% of U.S. healthcare systems and commercial payers will have used data on social determinants of some type in risk assessments, patient education and decisions commercial. Among the companies targeting SDOH are start-ups looking to focus directly on SDOH services and software, and larger, established entities that are excited about the potential benefits of SDOH. Large companies are designing new programs or looking to acquire smaller companies to launch their SDOH solutions. Considering the similarity with using data for population health management (PHM), data analytics and MPS companies are also keenly interested in the SDOH space. The common factor across the market is the need for robust data that can be used in developing new analytical models. SDOHs are truly data driven and will create a new big data opportunity in healthcare. There are many challenges that will need to be overcome for SDOH to realize its enormous potential. For example, some providers are concerned that SDOH may result in new and higher healthcare costs due to the complexity of adding new data to clinical protocols. Specifically, there are concerns that the SDOH implementation model is complex and difficult to standardize, and that the torrent of data threatens privacy and security. Also of concern is the fact that the vision for using SDOH is not systematically defined by regulators, industry advocates and companies that come up with relevant solutions. The study includes an overview of four notable companies in the SDOH space and reviews the types of products and services that make up SDOH solutions. A major service offered by pure SDOH companies is the ability to generate referrals that can lead patients and providers to a solution capable of transforming an SDOH problem into a healthier and more productive life.
Author: Victor Camlek
Read the full report: https://www.reportlinker.com/p06090608/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


		US Online Pharmacy Market Outlook and Forecasts 2021-2026: Key Players Are Kroger, CVS Health, CIGNA (Express Scripts), Walgreens Boots Alliance and Rite Aid – ResearchAndMarkets.com
		Wed, 09 Jun 2021 14:17:00 +0000


DUBLIN – (COMMERCIAL THREAD)–The “US Online Pharmacy Market – Industry Outlook and Forecast 2021-2026” report was added to ResearchAndMarkets.com offer.

The US online pharmacy market in terms of revenue is expected to grow at a CAGR of approximately. 19% over the period 2020-2026.

Automated prescription filling, automated customer relationship management, direct selling of drugs to patients are other major factors that are increasing the uptake of online pharmacies in the United States.

The market is moving towards the direct-to-patient model as the ever-expanding digital world opens doors to new services and user-friendly online experiences. The ease and familiarity of shopping online prompts many patients to seek out virtual care drugs and wellness options.

This has prompted online pharmacies to advertise more and acquire more consumers through digital platforms. The COVID-19 pandemic has further accelerated this change, as most healthcare professionals and patients have adapted to the virtual way of buying drugs. The trend is expected to increase dramatically in the United States after COVID-19.


The United States Online Pharmacy Market research report comprises detailed segmentation by drug type, product, modality, and pharmacy type. The US prescription online pharmacy market is expected to exceed $ 132 billion by 2026.

Profitability is an important factor in the growth of prescription drugs via the online mode. Consumers prefer to buy drugs from online stores because they offer drugs at lower prices than retail outlets. Among American adults taking prescription drugs, 1.5% reported purchasing drugs outside of the United States because of the high costs. Hence, online pharmacies are considered to be the best solution to provide prescription drugs at discounted prices, thus watching the growth.

In 2020, the drug segment represented approx. 76% market share of online pharmacies in the United States. The increase in the patient population as well as the increase in the geriatric population increases the demand for drugs. There is an increase in consumers preferring online pharmacy platforms to purchase drugs due to the great convenience of purchasing. Many customers and patients prefer to use online pharmacies to stock up on long-term medications.

The mobile application based segment is likely to grow at a CAGR of over 19% from 2020 to 2026. Mobile applications play an important role in the global online pharmacy market. They help online pharmacies get in direct contact with consumers, thereby increasing the patient base. Mobile applications help online pharmacies to effectively position their pharmacies.

Mobile apps offering prescription refills, secure two-way messaging, and a HIPAA-compliant mobile app will increase the number of online pharmacies. Providers prioritize digital advertising and marketing to attract more audiences, as many patients spend their time online.

The US online pharmacy market by the online brick and mortar branch expects to reach approx. $ 80 billion by 2026. Most retail businesses in the United States tend to have an online channel to promote their products and increase their customer base. This trend has prevailed in the United States for a long time. However, during the COVID-19 pandemic, the country further accelerated the adoption of online pharmacy channels.


The US online pharmacy market is experiencing a constant flow of start-ups entering the industry. The COVID-19 pandemic has increased the importance of online pharmacies in the country.

Many doctors, patients and health care providers have increased the adoption of telehealth, which has increased the number of teleconsultations in the country. Large hospitals received 500% more online consultations and electronic prescriptions among healthcare providers also increased.

These factors have accelerated the growth of the online pharmacy market in United States. A shift in consumer behavior patterns has increased the growth opportunities in the market. However, strict adherence to regulatory guidelines and the prevalence of counterfeiting and bogus websites selling unhealthy products are hampering the market.

Kroger, CVS Health, CIGNA (Express Scripts), Walgreens Boots Alliance and Rite Aid are the main players in the US online pharmacy market.

Main topics covered:

1 Research methodology

2 Research objectives

3 Research process

4 Scope and coverage

5 Hypotheses and caveats in the report

5.1 Key caveats

5.2 Currency conversion

5.3 Market derivation

6 Market overview

7 Presentation

7.1 Overview

7.2 Impact of COVID-19 on Us Online Pharmacy

7.3 Regulations for online pharmacies in the United States

7.4 Comparison of Electronic Pharmacy in US Market vs Global Market

7.5 Online pharmacy start-ups and their investments

8 Market opportunities and trends

8.1 Increase in direct sales of drugs to patients

8.2 Increased demand for advanced e-commerce technologies

8.3 High adoption of electronic prescriptions among US customers

9 market growth catalysts

9.1 Increase in teleconsultation and diagnostic assistance

9.2 Growing Penetration of Internet and Mobile Applications

9.3 High adoption of automated prescription renewal and CRM solutions

10 market restrictions

10.1 Sale of unapproved drugs and FDA warnings

10.2 Competition from traditional and medical product retailers

10.3 Strict regulatory framework for the online sale of medicines

11 Market landscape

11.1 Market overview

11.2 Market Size and Forecast

11.3 Analysis of the five forces

12 Type of drug

12.1 Market Overview and Growth Driver

12.2 Market overview

12.3 Prescription

12.4 Over The Counter (OTC)

13 Product

13.1 Market Overview and Growth Driver

13.2 Market overview

13.3 Medicines

13.4 Health, well-being and nutrition

13.5 Personal care

14 Modality

14.1 Market Overview and Growth Driver

14.2 Market overview

14.3 Mobile application

14.4 Web Based

15 Type of pharmacy

15.1 Market Overview and Growth Driver

15.2 Market overview

15.3 Online branch of the Brick & Mortar pharmacy

15.4 Independent online pharmacies only

15.5 Partnership site with neighborhood pharmacies

16 Competitive landscape

16.1 Competition overview

16.2 Market share analysis

Leading suppliers

  • Kroger

  • CVS Health

  • CIGNA (Express Scripts)

  • Alliance of Walgreens boots

  • Rite Help

Other important suppliers

  • Alto pharmacy

  • Flashing Health

  • BioPlus Specialized Pharmacy

  • Drug Batell

  • Carepoint pharmacy

  • Foundation care

  • Fruth Pharmacy

  • Giant eagle

  • Gogomeds.com

  • Health warehouse

  • High school pharmacy

  • Health for him and for her

  • Henry Ford Health System

  • Kinney Drugs

  • KwikMed

  • MedVantx

  • Medicine

  • Medly Pharmacy

  • Pharmacie du Nord-Ouest.com

  • OptumRx

  • Pillbox

  • Pharmacy Ro

  • Rx-24-online.com

  • Walmart Stores

  • Woori pharmacy

For more information on this report, visit https://www.researchandmarkets.com/r/cjgjx7

]]> Global Bronopol Industry Until 2026 https://resourcekt.co.uk/global-bronopol-industry-until-2026/ Tue, 08 Jun 2021 22:00:00 +0000 https://resourcekt.co.uk/global-bronopol-industry-until-2026/

DUBLIN, June 8, 2021 / PRNewswire / – The “Bronopol Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2021-2026” report was added to ResearchAndMarkets.com offer.

The global bronopol market has shown moderate growth during the period 2015-2020. Bronopol is a colorless, water-soluble organic compound produced by the bromination of di (hydroxymethyl) -nitromethane. It is supplied as crystals or as a crystalline powder, usually available in shades of white and pale yellow, depending on the iron content. It is very active against bacteria, fungi and yeasts and has high purity and tensile strength. Its biocidal uses include disinfection, product preservation, as well as fiber, leather and rubber preservation. Due to its antimicrobial properties, it is widely used in the manufacture of drugs, cosmetics, and personal care products such as lotions, makeup, perfumes, and shampoos. Looking ahead, the publisher expects the global bronopol market to grow at a CAGR of around 5% during 2021-2026.

The growing demand for potable water across the world is the key factor for the market growth. Bronopol is widely used in several water treatment plants to meet this ever increasing demand as it kills various types of bacteria present in the water and makes it safe for consumption. Since water is an integral part of industrial and residential activities, it contributes more to the demand for products. Additionally, industrial water systems are a potential environment for bacterial growth and Bronopol helps prevent corrosion and sludge contamination in industrial water recirculation plants. Moreover, the growing consumer health awareness regarding diseases caused by waterborne pathogens and bacterial growth is catalyzing the growth of the market. In addition, growing activities in the oil and gas industry where Bronopol is used to prevent corrosion from bacterial contamination in hydraulic fracturing equipment is driving product demand.

This report provides an in-depth overview of the global Bronopol market covering all its essential aspects. It ranges from macro market overview to micro details of industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, ‘value chain analysis, etc. This report is must-read for industry players, investors, researchers, consultants, business strategists, and anyone with any interest in or planning to foray into the Bronopol market in any way.

Competitive landscape:

The report also analyzed the competitive landscape of the market with some of the major players being BASF, Fujian Shaowu, Gayathri Chemicals and Agencies, The Dow Chemical Company, Symbolic Pharma, Shanghai Rich Chemicals, Sharon Laboratories, Mani Agro Chemicals, Sai Supreme Chemicals, BQ Technology (HK) Company, Wuhan Fortuna Chemical, Weifang Haihua Yuanda Fine Chemicals, etc.

Key questions addressed in this report:

  • How has the global bronopol market performed so far and how will it perform in the years to come?
  • What are the major regional markets for the global bronopol industry?
  • What has been the impact of COVID-19 on the global bronopol industry?
  • What is the market breakdown according to type?
  • What is the market break according to the form?
  • What is the market split depending on the application?
  • What are the different stages of the global bronopol industry value chain?
  • What are the major factors and driving challenges for the global bronopol industry?
  • What is the structure of the global bronopol industry and who are the main players?
  • How competitive is the global bronopol industry?

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Bronopol Global Market
5.1 Market overview
5.2 Market performance
5.3 Impact of COVID-19
5.4 Market breakdown by type
5.5 Market breakdown by form
5.6 Market Split by Application
5.7 Market breakdown by region
5.8 Market forecast

6 Market breakdown by type
6.1 Coagulants and flocculants
6.1.1 Market trends
6.1.2 Market Forecast
6.2 Biocides and disinfectants
6.2.1 Market trends
6.2.2 Market Forecast
6.3 PH adjusters and stabilizers
6.3.1 Market trends
6.3.2 Market Forecast
6.4 Inhibitors
6.4.1 Market trends
6.4.2 Market Forecast
6.5 Defoamers
6.5.1 Market trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market trends
6.6.2 Market Forecast

7 Market breakdown by form
7.1 Liquid
7.1.1 Market trends
7.1.2 Market Forecast
7.2 Solid
7.2.1 Market trends
7.2.2 Market Forecast

8 Market breakdown by application
8.1 Water treatment
8.1.1 Market trends
8.1.2 Market Forecast
8.2 Formulators
8.2.1 Market trends
8.2.2 Market Forecast
8.3 Oil and gas
8.3.1 Market trends
8.3.2 Market Forecast
8.4 Paper and pulp
8.4.1 Market trends
8.4.2 Market Forecast
8.5 Paints, coatings and adhesives
8.5.1 Market trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market trends
8.6.2 Market Forecast

9 Market breakdown by region
9.1 North America
9.1.1 Market trends
9.1.2 Market Forecast
9.2 Asia Pacific
9.2.1 Market trends
9.2.2 Market Forecast
9.3 Europe
9.3.1 Market trends
9.3.2 Market Forecast
9.4 Latin America
9.4.1 Market trends
9.4.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market trends
9.5.2 Market Forecast

10 SWOT Analysis

11 Value chain analysis

12 Porter’s Five Forces Analysis

13 Price analysis

14 Competitive landscape
14.1 Market structure
14.2 Key players
14.3 Profiles of key players
14.3.1 BASF
14.3.2 Fujian Shaowu
14.3.3 Gayathri Chemicals and agencies
14.3.4 The Dow Chemical Company
14.3.5 Symbolic Pharma
14.3.6 Shanghai Rich Chemicals
14.3.7 Sharon Laboratories
14.3.8 Mani Agro Chemicals
14.3.9 Supreme Sai Chemicals
14.3.10 BQ Technology Company (HK)
14.3.11 Wuhan Fortuna Chemical
14.3.12 Weifang Haihua Yuanda Fine Chemicals

For more information on this report, visit https://www.researchandmarkets.com/r/t350zw

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links


Global Autonomous Vessels Market Report 2021-2030: Rising https://resourcekt.co.uk/global-autonomous-vessels-market-report-2021-2030-rising/ Tue, 08 Jun 2021 08:23:37 +0000 https://resourcekt.co.uk/global-autonomous-vessels-market-report-2021-2030-rising/

Dublin, June 08, 2021 (GLOBE NEWSWIRE) – The “Global Autonomous Vessels Market Report 2021: Growth and Change of COVID-19 through 2030” report was added to ResearchAndMarkets.com offer.

The main players in the autonomous vessel market are General Electric, DNV GL, Rolls-Royce Holding PLC, Kongsberg Gruppen AS, NYK Line, Mitsui E&S Holdings Co Ltd, Wartsila Corporation, DSME Co., Ltd., Vigor Industrial LLC. and Praxis Automation Technology BV

The global autonomous vessel market is expected to grow from $ 5.68 billion in 2020 to $ 6.46 billion in 2021 at a compound annual growth rate (CAGR) of 13.7%.

The growth is primarily driven by businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, the remote work and closure of business activities which resulted in operational challenges.

The market is expected to reach $ 9.24 billion in 2025 at a CAGR of 9%.

The increase in maritime accidents caused by human error leads to high financial losses which are expected to be a major driver for the growth of the autonomous vessels market. Unmanned vessels or autonomous technology capture accidents due to human error and contribute to the higher potential for reduction of accidents on board.

The growing threat of cybersecurity and privacy is expected to limit the growth of the Autonomous Vessels market during the forecast period. Advances in technology and the adoption of artificial intelligence (AI), mobility systems and the Internet of Things (IoT) create increased cybersecurity risks and data threats, posing a major challenge for the autonomous ship industry.

According to the Association for Computing Machinery (ACM) Autonomous Vessel Cybersecurity Journal, cybersecurity is a serious issue for autonomous vessels, regardless of vessel shape and level of autonomy, due to their dependence increased use of ICTs to control the vessel, accessibility of systems to the Internet and increased connectivity of the vessel control system to on-shore monitoring systems. Thus, the growing threat to cybersecurity and privacy is expected to be a major factor restraining the Autonomous Vessels market over the next few years.

The Autonomous Vessels market covered in this report is segmented by Autonomous into Fully Autonomous; remote operations; partially autonomous and by the end user in commercial; defense.

Large companies are undertaking various strategic initiatives such as the development of fully autonomous ships, which is likely to be a major trend driving the growth of the autonomous ship industry. For example, according to Offshore Energy news published in December 2018, Rolls Royce, a technology company, and Finferries, a state-owned ferry operator demonstrated the world’s first fully autonomous ferry in the archipelago south of the city of Turku, Finland.

He used a combination of intelligence technology from Rolls Royce ships in order to navigate autonomously during his voyage between Paraninen and Nauvo. the development of total autonomy is a major trend which should offer growth opportunities to the market.

In May 2018, Wartsila Corporation, the technology group announced the acquisition of Transas, a UK-based company for $ 257.8 million. This acquisition is part of Wartsila Corporation’s attempt to broaden the vision of the company’s intelligent marine ecosystem.

The smart marine ecosystem is a vision where smart ships connect to smart ports to improve operational efficiency and resource use to reduce risk and impact on the environment by improving safety and security. safety. Transas was founded in 1990 and is a provider of vessel and fleet operations solutions that include access to information for real-time information, digital data and electronic chart services, and infrastructure for bridge.

Main topics covered:

1. Summary

2. Characteristics of the autonomous vessel market

3. Autonomous Vessels Market Trends and Strategies

4. Impact of COVID-19 on autonomous vessels

5.Size and Growth of Autonomous Vessels Market
5.1. Global Historic Autonomous Vessel Market, 2015-2020, in USD Billion
5.1.1. Market drivers
5.1.2. Market restrictions
5.2. Global Autonomous Ship Forecast Market, 2020-2025F, 2030F, in USD Billion
5.2.1. Market drivers
5.2.2. Market constraints

6. Market segmentation of autonomous vessels
6.1. Global Autonomous Vessels Market, Segmentation by Autonomy, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

  • Fully autonomous
  • Remote operations
  • Partial autonomous

6.2. Global Autonomous Vessels Market, Segmentation by End User, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

6.3. Global Autonomous Vessels Market, Segmentation by Propulsion Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

6.4. Global Autonomous Vessels Market, Fuel Type Segmentation, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

  • Carbon neutral fuels
  • LNG, Electric
  • Heavy fuel oil / marine engine fuel

7. Regional and National Analysis of Autonomous Vessels Market
7.1. Global Autonomous Vessel Market, Divided by Region, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion
7.2. Global autonomous vessel market, divided by country, historical and forecast, 2015-2020, 2020-2025F, 2030F, in billions of dollars

Companies mentioned

  • General Electric
  • DNV GL
  • Rolls-Royce Holding PLC
  • Kongsberg Gruppen AS
  • NYK Line
  • Mitsui E&S Holdings Co Ltd
  • Wartsila Company
  • DSME Co.
  • Ltd.
  • Vigor Industrial LLC.
  • Praxis Automation Technology BV
  • Valmet Corp
  • Automated Ships Ltd.
  • ASV Global
  • Rh Marin
  • L3 ASV
  • Siemens

For more information on this report, visit https://www.researchandmarkets.com/r/gzr941

		Mythic AI Targets Edge AI Market With New Smaller, More Energy-Efficient M1076 Chips
		Mon, 07 Jun 2021 20:51:13 +0000


It has been a busy seven month period for the AI ​​Mythic AI chip to start up. Seven months ago, the company unveiled its first M1108 Analog Matrix Processor (AMP) for AI inference. A month ago, Mythic AI announced a new round of $ 70 million Series C investment to bring its chips to mass production and develop its next hardware and software products.

Today, June 7 (Monday), the startup announced the arrival of its second chip design, the new M1076 AMP, which has a smaller form factor and lower power requirements than the original M1076 chip. so that it can be a better fit and better choice for the needs of smaller AI devices and applications.

Packing up to 25 TOPs in a single chip, the AMP M1076 will be available in three form factors: a stand-alone chip, a compact 22mm x 30mm PCIe M.2 A + E key card, or a loaded PCIe card. 16 M1076 chips totaling 400 TOPS and 1.28 billion in weight, while consuming 75 watts, according to the company.

Tim Vehling from Mythic AI

The arrival of the new chip only seven months after the launch of the first M1108 chips was expected and is the result of the fact that many potential customers need a smaller, more energy efficient chip, Tim vehling, the senior vice president of product and business development at Mythic AI, said Corporate AI.

“We’re basically showing that we can derive and generate different versions of the technology quite easily” to meet customer needs, Vehling said. “One of the promises of the architecture is that you can quickly come up with larger or smaller versions and that’s what it shows.”

So far Mythic AI does not ship any chips to customers, he said, but the plan is to ship the M1076 chips by the end of 2021 or early 2022.

“We have sampled the original M1108 chips with customers,” Vehling said. “We will be delivering the first samples of this new M1076 product next month. We will see what customers go into production with, with which. But I think this version is ideal from a size, performance and horsepower perspective.

The design of the second chip was planned earlier to provide customers with a variety of chips to choose from for use in their products, he said.

Mythic AI’s new smaller M1076 AI chip

“It turns out that in a PC world, the larger size [of the original M1088 chip] isn’t a problem, but if you want to have a strong presence in the embedded world, with embedded products using Arm-based processors, ”the components have to be smaller, Vehling said. “As we engage customers, we basically have to make our product a lot more scalable from the different form factors. “

Mythic AI is factory-free with all of its chips manufactured by UMC Japan.

Additional AI chips from Mythic AI are in the works and are expected in the future, Vehling said.

“If you look at the architecture, we call a tile architecture, you can see an array of these little tiles, the exact same tile is reproduced on the chip,” he said. “So we can certainly size what is needed based on the application that we see. One of the advantages of our architectures is that we use cheaper and older 40 nanometer process technology. So, it is quite easy for us to make versions or derivatives. It is not a big effort for us.

The biggest original M1108 AI chip from Mythic AI

The M1076 AMP is designed for use in endpoints as well as server applications for a wide range of uses including smart cities, industrial applications, enterprise applications, consumer devices and more. The M1076 AMP is also suitable for video analysis workloads, including object detection, classification and depth estimation for machine vision, autonomous drones, surveillance cameras and recording applications. network video. It can also support AR / VR applications with low latency human body pose estimation, which should drive future smart fitness, gaming and collaborative robotics devices, according to the company.

The company’s ME1076 PCIe M.2 A + E Key and MM1076 PCIe M.2 M Key cards are expected to be available for customer review from July 2021.

Smaller chip makes good sense: analysts

Dan Olds, Analyst

Offering the new smaller M1076 AMP chip is a smart move from Mythic AI, Dan Olds, research director for Intersect360 Research, said Corporate AI. “This is their second chip design, but it seems to better meet customers’ size and usage requirements. “

Offering it in multiple configurations and performance levels is also a good thing, he said. “For AI inference, this gives customers a wide range of form factors: they can use the stand-alone processor in their own sensors to provide on-board inference capability, or use the large 16-processor board in a data center. data. There is also a third option that sits in an M.2 drive slot on a motherboard, adding more options for customers. All of them are very energy efficient, which is a requirement for anything remote on the outskirts. “

Like all the other AI chip companies competing to create the next big innovation in AI chips, Mythic AI is looking for market leader Nvidia, which has made a fortune producing GPU compute accelerators, Olds said. . “Nvidia’s GPU revenues have more than doubled in the past year, which is a huge target on their backs.”

But if there is a lot of competition, Mythic AI is well placed, he said.

“Mythic, with its analog processors, is ahead of the game when it comes to inference processors,” Olds said. “This is a very innovative approach and not likely to be copied. If they can perform and really prove their worth, they could be one of the big winners in the AI ​​gold rush. One point in their favor is that they recently closed another round of funding, this time for $ 70 million, which will be used to increase production and, from what I can understand, establish a commercial presence in the whole world.

Alex Norton, Analyst

Another analyst, Alex Norton, senior technology analyst and head of data analytics for HPC and emerging technologies at Hyperion Research, said he was particularly excited about Mythic AI’s different approach to designing AI chips.

“The key point that grabs me about their ad and their platform is the chip’s power consumption,” Norton said. “AI accelerators and processors can be very power hungry, so building one that is more power efficient is an important distinction for Mythic. Especially since they target inference applications at the edge where power may be more limited than in a data center environment. “

More importantly, he added, the company listens to its potential customers when planning its products.

“Mythic’s announcement highlights that AI chip startups are focused on specific applications and use cases for their technology, working closely with end users to deliver products tailored to their needs.” Norton said. “The low-power, compact form fits their use cases exactly. “

Including the $ 70 million in Series C funding that Mythic AI provided in May, the company has now raised $ 165.2 million.

Global NT 3 Growth Factor Receptor Market 2021-2026 Financial Outlook, Company Growth Strategies with Major Players | Major players: Array BioPharma Inc, Plexxikon Inc, Handok Inc, AstraZeneca Plc, Netris Pharma SAS, etc. – KSU https://resourcekt.co.uk/global-nt-3-growth-factor-receptor-market-2021-2026-financial-outlook-company-growth-strategies-with-major-players-major-players-array-biopharma-inc-plexxikon-inc-handok-inc-astrazeneca-plc-n/ Mon, 07 Jun 2021 02:58:25 +0000 https://resourcekt.co.uk/global-nt-3-growth-factor-receptor-market-2021-2026-financial-outlook-company-growth-strategies-with-major-players-major-players-array-biopharma-inc-plexxikon-inc-handok-inc-astrazeneca-plc-n/

Reports Globe offers a global study and analysis based on the research of the NT Growth Factor Receptor Market 3. This report provides a detailed overview of the drivers and limitations available in the market. The NT 3 Growth Factor Receptor market report also provides prehistoric and five-year forecasts for the industry and contains socio-economic data around the world. Key stakeholders can view statistics, tables and figures mentioned in this strategic planning report that lead to organizational success. Illuminates strategic production, revenue, and consumption trends for gamers to increase sales and growth in the global NT 3 Growth Factor Receptor Market. Here, it focuses on the latest developments, sales, market value, production, gross margin, and other important business factors of major players operating in the global NT 3 Growth Factor Receptor Market. Players can use the exact market facts, figures, and statistical studies provided in the report to understand the current and future growth of the global NT3 Growth Factor Receptor Market.

This report provides an assessment of various drivers, government policies, technological innovations, emerging technologies, opportunities, market risks, restraints, market barriers, challenges, trends, competitive landscapes, and segments which provide a true picture of the growth of the global market to through NT 3 Growth Factor Receptor Market.

Get a FREE copy of this report at: https://reportsglobe.com/download-sample/?rid=112870

The main key players presented in this report are:

  • Array BioPharma Inc
  • Plexxikon Inc
  • Handok Inc
  • AstraZeneca Plc
  • Netris Pharma SAS
  • Daiichi Sankyo Company Ltd
  • Loxo Oncology Inc
  • Ignyta Inc

    The report is an assortment of first-hand information, subjective and quantitative assessments by industry specialists, contributions from industry reviewers and members of the NT 3 Growth Factor Receptor industry on the value chain . The report offers a top-to-bottom study of parent market patterns, macroeconomic measures, and control components. In addition, the report also reviews the subjective effect of undeniable market factors on market sections and geologies of the NT 3 Growth Factor Receptor Market.

    NT Growth Factor Receptor 3 Market Segmentation:

    Based on type

  • AZD-7451
  • Larotrectinib
  • DS-6051
  • LM-22B10
  • Other

    App based

  • Breast cancer
  • Brain cancer
  • Solid tumor
  • Colon Cancer
  • Fibrosarcoma
  • Other

    Global NT Growth Factor Receptor 3 Market: Regional Segments

    The various sections on regional segmentation give regional aspects of the Growth Factor NT 3 Receptor Global Market. This chapter describes the regulatory structure likely to have an impact on the entire market. It highlights the political landscape of the market and predicts its influence on the NT 3 growth factor receptor market globally.

    • North America (United States, Canada)
    • Europe (Germany, United Kingdom, France, rest of Europe)
    • Asia Pacific (China, Japan, India, rest of Asia-Pacific)
    • Latin America (Brazil, Mexico)
    • Middle East and Africa

    Get up to 50% off this report at: https://reportsglobe.com/ask-for-discount/?rid=112870

    What to expect from the report?

    1. Total Size of the Growth Factor Receptor NT 3 Available Market (TAM)
    2. Growth Factor Receptor NT 3 Available in Service (SAM) Market Size
    3. Business implications of COVID-19 in the global market
    4. Market share / revenue share (%) of major market players in total market size (2019)
    5. Market Size and Forecast (2016-2027) Nationally and Regionally, by Segments
    6. Overview and analysis of the major players operating in the market

    NT 3 Growth Factor Receptor Industry focuses on the leading leading players in the industry providing information such as company profiles, product image and specifications, capacity, production, price, cost, income and contact details. Upstream raw material and equipment and downstream demand analyzes are also performed. Global NT 3 Growth Factor Receptor market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and general research conclusions are proposed. Together with tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

    The objectives of the study are:

    1. To analyze and research global NT Growth Factor Receptor 3 status and future forecast involving production, revenue, consumption, historical data and forecast.
    2. To introduce key manufacturers, production, revenue, market share and recent development of NT 3 Growth Factor Receptor.
    3. To divide breakdown data by regions, types, manufacturers and applications.
    4. To analyze the potential and advantages of the global market and key regions, opportunities and challenges, restraints and risks.
    5. To identify important trends, drivers, influencing factors in the world and regions.
    6. Analyze competitive developments such as extensions, agreements, new product launches and acquisitions in the market.

    Ask your questions about personalization to: https://reportsglobe.com/need-customization/?rid=112870

    How Reports Globe is different from other market research providers:

    The creation of Reports Globe was supported by providing clients with a holistic view of market conditions and future possibilities / opportunities to derive maximum profit from their businesses and assist in decision making. Our team of in-house analysts and consultants work tirelessly to understand your needs and come up with the best possible solutions to meet your research needs.

    Our Reports Globe team follows a rigorous data validation process, which allows us to publish editor’s reports with minimal or no deviation. Reports Globe collects, separates and publishes more than 500 reports per year covering products and services in many fields.

    Contact us:

    Mr. Mark Willams

    Account manager

    United States: + 1-970-672-0390

    E-mail: sales@reportsglobe.com

    Website: Reportsglobe.com

  • ]]>
    Glial Cell Line Derived Neurotrophic Factors Market To Show Healthy Annual Growth Rate Over 2021-2026 Period https://resourcekt.co.uk/glial-cell-line-derived-neurotrophic-factors-market-to-show-healthy-annual-growth-rate-over-2021-2026-period/ Sun, 06 Jun 2021 02:59:27 +0000 https://resourcekt.co.uk/glial-cell-line-derived-neurotrophic-factors-market-to-show-healthy-annual-growth-rate-over-2021-2026-period/

    The latest glial cell line-derived neurotrophic factor market study offers a comprehensive analysis of information gathered over the past few years with the aim of predicting information for years to come. This is facilitated by the graphical presentation of the data in the form of tables, charts and graphs. to give the reader a clear understanding of the market. The information provided in the study draws attention to market size, trends, gross sales, volume, growth drivers, expert opinions, key facts and figures and other cutting edge information. to provide accurate market estimates. The research report offers valuable insights into the Glial Cell Line Derived Neurotrophic Factor market report by examining key industry insights.

    The scientific literature on the Glial Cell Line Derived Neurotrophic Factor market extensively studies this industry vertical by explaining key development trends, limitations, challenges, and opportunities that will shape business dynamics in the coming years. Going deeper, it highlights key regional markets and reveals key areas of business development, while providing a comprehensive account of leading companies in this area. Apart from this, it also assesses the impact of the COVID-19 pandemic on revenue generation and breaks down the business strategies used by well-established organizations to adapt to changes in this industry.

    Main highlights of the Covid-19 impact assessment:

    • Impact of the Covid-19 pandemic on the global economy.
    • Variations in supply and demand due to disruption of distribution channels.
    • Initial and future analysis of the impact of the pandemic on business growth.

    Request a copy of this report @ https://www.business-newsupdate.com/request-sample/135870

    An overview of the regional analysis:

    • Geographically, the Glial Cell Line Derived Neurotrophic Factor market is categorized as North America, Europe, Asia Pacific, South America, Middle East and Africa.
    • A summary of each regional market, including their compound annual growth rate over the analysis period, is attached to the document.
    • The total sales and net income by each geographic area is also cited.

    Additional takeaways from the Glial Cell Line Derived Neurotrophic Factor Market report:

    • Speaking of product terrain, the Glial Cell Line Derived Neurotrophic Factor Market is segmented into
      • GSK-812
      • LAUR-301
      • TW-002
      • AMT-090 and others


    • Volume and revenue projections based on data for each product type are provided.
    • Information on the annual growth rate and market share of each product category during the forecast period is provided.
    • Based on the spectrum of applications, the vertical industry is segmented into
      • Amyotrophic lateral sclerosis
      • Cerebral ischemia
      • Parkinson’s disease
      • Retinal degeneration
      • Other
      • Geographically
      • detailed production analysis
      • the trade of the following countries is covered in chapter 4.2
      • 5:
      • United States
      • Europe
      • China
      • Japan and India


    • The compound annual growth rates of each application segment during the stipulated period are underlined.
    • Leading Glial Cell Line Derived Neurotrophic Factor Market Organizations Are
      • UniQure SA
      • Treeway BV and GlaxoSmithKline Plc


    • Detailed profiles of the companies mentioned based on their manufacturing capacity, industry compensation, and product offerings are hosted in the report.
    • Other important business aspects such as the pricing models, market share and gross margins of each company are also presented.
    • The main competitive trends as well as their effects on companies are fully discussed.
    • The study also incorporates a detailed analysis of the industry’s supply chain in terms of upstream and downstream bases and distribution channels.
    • The report interprets the feasibility of investing a potential project by leveraging SWOT analysis and Porter’s five forces assessment.

    Some points from the table of contents

    Chapter 1 Glial Cell Line Derived Neurotrophic Factor Market Introduction and Market Overview

    Chapter 2 Executive Summary

    Chapter 3 Industry Chain Analysis

    Chapter 4 Global Glial Cell Line Derived Neurotrophic Factors Market, By Type

    Chapter 5 Glial Cell Line Derived Neurotrophic Factor Market, By Application

    Chapter 6 Global Glial Cell Line Derived Neurotrophic Factors Market Analysis by Regions

    Chapter 7 North America Glial Cell Line Derived Neurotrophic Factors Market Analysis by Countries

    Chapter 8 Europe Glial Cell Line Derived Neurotrophic Factors Market Analysis by Countries

    Chapter 9 Asia-Pacific Glial Cell Line Derived Neurotrophic Factors Market Analysis by Countries

    Chapter 10 Middle East & Africa Glial Cell Line Derived Neurotrophic Factors Market Analysis by Countries

    Chapter 11 South America Glial Cell Line Derived Neurotrophic Factors Market Analysis by Countries

    Chapter 12 Competitive Landscape

    Chapter 13 Industry Outlook

    Chapter 14 Global Glial Cell Line Derived Neurotrophic Factor Market Forecast

    Chapter 15 Feasibility analyzes of a new project

    Request customization on this report @ https://www.business-newsupdate.com/request-for-customization/135870

    The best service providers partner with medical laboratories, pharmacies, blood centers, home care agencies and veterinary laboratories https://resourcekt.co.uk/the-best-service-providers-partner-with-medical-laboratories-pharmacies-blood-centers-home-care-agencies-and-veterinary-laboratories/ Fri, 04 Jun 2021 22:45:00 +0000 https://resourcekt.co.uk/the-best-service-providers-partner-with-medical-laboratories-pharmacies-blood-centers-home-care-agencies-and-veterinary-laboratories/

    DUBLIN, June 4, 2021 / PRNewswire / – The “Medical Messaging Services Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecast, 2021-2029” report was added to ResearchAndMarkets.com offer.

    The global medical courier market is growing steadily as a direct result of the upward trends in the same day delivery and express delivery segment. The expansion of healthcare transport / logistics and the growing demand for faster delivery of samples and samples for diagnostic or testing purposes are driving maximum revenue share in the market.

    In addition, manufacturers focus on reducing logistics costs as well as improving the healthcare delivery model in various fields such as pharmaceutical and biotechnology industries, hospitals, medical laboratories, clinics and services. public health.

    The growing need for samples and equipment in the pharmaceutical and biotechnology industries will enhance the overall expansion of the medical messaging market globally. Various multinational medical messaging service providers offer 24/7 or STAT services with more security and faster response times.

    On-time delivery and route optimization are vital for medical couriers, as items such as samples and other organ specimens are unusable if not delivered on time. The growing need for organ transplants is a crucial factor that complements the overall growth of the medical courier market.

    However, the risk of compromising quality due to the rush to deliver the products in the shortest time and the lack of qualified personnel hinders overall growth in developing countries. In addition, the dependence on their own services by hospitals with limited external logistical support limits market growth in a few regions.

    Pharmaceutical and biotechnology companies will experience significant growth

    Medical courier services are showing successful growth in the pharmaceutical and biotechnology segment. Manufacturers and distributors use third-party services at reasonable rates compared to conventional in-house shipping charges. Various small-scale service providers offer specialized solutions such as same day delivery, STAT delivery, express delivery and shipment tracking. In addition, the hospital and clinic segment is expected to dominate the market during the forecast period owing to the increasing demand and adoption of medical supplies by these healthcare facilities.

    Improved global logistics as well as logistics for clinical trials, cell and gene therapy, and direct-to-patient models are driving growth in the applications segment. Standard supply chain services as well as customized services for pharmaceutical storage and other industrial solutions will experience exponential growth during the forecast period.

    Strong demand and presence of the best players North America in a dominant position

    Now, North America (mainly the United States) generates a share of the revenue in the global market due to the presence of some of the largest providers of medical messaging services. Improved clinical supply model as well as commercial distribution will drive revenue growth during the forecast period.

    The best service providers are observed to partner with medical laboratories, pharmacies, blood centers, home health agencies and veterinary laboratories around the world. Multinational companies ensure rapid transportation of supplies while eliminating fragmentation and redundancies with a centralized and streamlined process reducing the overall cost of shipping.

    On the other hand, the growing establishment of Special Economic Zones (SEZs), Export Processing Zones (EPZs) and Free Zones (FTAs) by various Asian governments has a supporting role in the lucrative growth of the export market. Asia Pacific.

    Other important factors include business opportunities in the private sector and the development of cross-border e-commerce of physical goods contributes to a significant market share in the market. However, high cost, limited availability of courier services for clinical supplies, understaffing, and complexity of customs, export procedures, and documentation limit the growth of medical courier market.

    Predominance of multinational service providers with a strong brand image in developed regions

    Larger companies are launching faster and safer express delivery in developed countries. In addition, acquisitions, collaborations, partnerships with smaller service providers, healthcare organizations and public health companies will further drive revenue growth in the years to come.

    Key questions answered in this report

    • What are the current and future trends in the medical messaging market?
    • What are the prevailing dynamics in the private messaging sector and the interesting opportunities for emerging players?
    • How is the demand and shortage of medical mail affecting the global market?
    • How is medical mail advancing in developing economies alongside import-export consumption?
    • Which application segment represents the fastest CAGR during the forecast period?
    • What type of application has a significant market share and why?
    • What is the impact of the high cost of same day delivery and express delivery on the medical courier market?
    • Which services and brands in the medical messaging industry are experiencing the greatest growth and why?
    • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America and Middle East & Africa?

    Main topics covered:

    Chapter 1. Preface

    Chapter 2. Executive summary

    Chapter 3. Global Medical Mail (CM) Market: Market Dynamics and Future Prospects

    Chapter 4. Global Medical Courier (CM) Market, by Application, 2019-2029 (Million US $)

    Chapter 5. Global Medical Courier (CM) Market, By Geography, 2019-2029 (USD Million)

    Chapter 6. Company Profiles

    • FedEx Corporation
    • DHL International GmbH
    • Amecord Registry LLC
    • Global Logistics Network
    • United Parcel Service of America Inc.
    • Medical Couriers Inc.
    • Medical Courrier Services Ltd.
    • Aylesford Couriers Ltd.
    • CitySprint (UK) Ltd
    • Services Express MedLine inc.
    • IntelliQuick Delivery Inc.
    • Blaze Express Courier Service

    For more information on this report, visit https://www.researchandmarkets.com/r/f2oeq3

    Media contact:

    Research and markets
    Laura Wood, senior
    [email protected]

    For EST office hours, call + 1-917-300-0470
    For USA / CAN call toll free + 1-800-526-8630
    For GMT office hours, call + 353-1-416-8900

    US Fax: 646-607-1907
    Fax (outside the United States): + 353-1-481-1716

    SOURCE Research and Markets

    Related links